CYBERDYNE Inc. CYBQY OTC · Healthcare · Japan
$1.14 -7.17% -$0.09
Summary
34 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: ¥13.0B against ¥536.4M.
- The share price is below the Bulios Fair Price.
What to watch
- Revenue growth is slowing: 7.4% a year over the last 3 years against 17% over 5 years.
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 125.2 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 17% a year over 5 years. Over the last 3 years it grew by 7.4% a year.
Growth in detailDoes it make money?
PoorlyWhere 100 JPY of revenue goes
- Cost of sales 51 JPY
- Research and development 25 JPY
- Sales and administration 52 JPY
- Taxes and other -34 JPY
- Net profit 7.1 JPY
Net profit, industry median (Medical - Devices) 6.6 JPY
Out of every 100 JPY of revenue, 7.1 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.